ABCR  Vol.2 No.3 , July 2013
Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer
Abstract: Background: Metastatic breast cancer in BRCA 2 patients is lacking of target therapy studies. Case: We present a case of a 34-year-old woman affected by a recurrent metastatic breast cancer after 5 years treated with weekly nab-paclitaxel and three weekly Cisplatin obtaining a radiological complete response with 6 cycles. Conclusion: It is important to emphasize that patients with a molecular disorder who selected for “target” chemotherapy can obtain optimal response rate. Exploiting the mechanism of action of DNA damage in our favor, using cisplatin for example and basing on literature show the efficacy of using taxane in BRCA 2 patients, obtaining a very high response rate.
Cite this paper: Artioli, G. , Azzarello, G. , Meggiolaro, F. , Wabersich, J. , Borgato, L. and Bari, M. (2013) Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer. Advances in Breast Cancer Research, 2, 56-59. doi: 10.4236/abcr.2013.23010.

[1]   D. Ford, D. F. Easton and J. Peto, “Estimates of the Gene Frequency of BRCA1 and Its Contribution to Breast and Ovarian Cancer Incidence,” American Journal of Human Genetics, Vol. 57, No. 6, 1995, pp. 1457-1462.

[2]   D. Ford, D. F. Easton, M. Stratton, S. Narod, D. Goldgar, P. Devilee, D. T. Bishop, B. Weber, G. Lenoir, J. ChangClaude, H. Sobol, M. D. Teare, J. Struewing, A. Arason, S. Scherneck, J. Peto, T. R. Rebbeck, P. Tonin, S. Neuhausen, R. Barkardottir, J. Eyfjord, H. Lynch, B. A. Ponder, S. A. Gayther and M. Zelada-Hedman, “Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families. The Breast Cancer Linkage Consortium,” American Journal of Human Genetics, Vol. 62, No. 3, 1998, pp. 676-689. doi:10.1086/301749

[3]   A. Antoniou, P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord, J. L. Hopper, N. Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, D. M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjakoski, O. P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D. G. Evans and D. F. Easton, “Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies,” American Journal of Human Genetics, Vol. 72, No. 5, 2003, pp. 1117-1130. doi:10.1086/375033

[4]   G. von Minckwitz, S. Loibl, A. Maisch and M. Untch, “Lessons from the Neoadjuvant Setting on How Best to Choose Adjuvant Therapies,” Breast (Edinburgh, Scotland), Vol. 20, No. S3, 2011, pp. S142-S145.

[5]   K. A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks, R. Yerushalmi, E. Macpherson, J. Carmichael and A. Oza, “Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study,” The Lancet Oncology, Vol. 12, No. 9, 2011, pp. 852-861. doi:10.1016/S1470-2045(11)70214-5

[6]   B. Arun, S. Bayraktar, D. D. Liu, A. M. Gutierrez Barrera, D. Atchley, L. Pusztai, J. K. Litton, V. Valero, F. MericBernstam, G. N. Hortobagyi and C. Albarracin, “Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, Vol. 9, No. 28, 2011, pp. 3739-3746.

[7]   P. Domagala, T. Huzarski, J. Lubinski, K. Gugala and W. Domagala, “PARP-1 Expression in Breast Cancer Including BRCA1-Associated, Triple Negative and Basal-Like Tumors: Possible Implications for PARP-1 Inhibitor Therapy,” Breast Cancer Research and TREATMENt, Vol. 127, No. 3, 2011, pp. 861-869. doi:10.1007/s10549-011-1441-2

[8]   T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wisniowski, M. Siolek, R. Dent, J. Lubinski and S. Narod, “Pathologic Complete Response Rates in Young Women with BRCA1-Positive Breast Cancers after Neoadjuvant Chemotherapy,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, Vol. 28, No. 3, 2010, pp. 375-379. doi:10.1200/JCO.2008.20.7019

[9]   M. Kriege, A. Jager, M. J. Hooning, E. Huijskens, J. Blom, C. H. van Deurzen, M. Bontenbal, J. M. Collee, M. B. Menke-Pluijmers, J. W. Martens and C. Seynaeve, “The Efficacy of Taxane Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers,” Cancer, Vol. 118, No. 4, 2012, pp. 899-907. doi:10.1002/cncr.26351

[10]   F. Huang, Y. B. Kushner, A. Langleben, W. D. Foulkes and Medscape, “Eleven Years Disease-Free: Role of Chemotherapy in Metastatic BRCA2-Related Breast Cancer,” Nature Reviews. Clinical Oncology, Vol. 6, No. 8, 2009, pp. 488-492.

[11]   W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins and J. O’Shaughnessy, “Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, Vol. 23, No. 31, 2005, pp. 7794-7803.

[12]   N. P. Desai, V. Trieu, L. Y. Hwang, R. Wu, P. Soon-Shiong and W. J. Gradishar, “Improved Effectiveness of Nanoparticle Albumin-Bound (Nab) Paclitaxel Versus Polysorbate-Based Docetaxel in Multiple Xenografts as a Function of HER2 and SPARC Status,” Anti-Cancer Drugs, Vol. 19, No. 9, 2008, pp. 899-909. doi:10.1097/CAD.0b013e32830f9046

[13]   A. Veronesi, C. de Giacomi, M. D. Magri, D. Lombardi, M. Zanetti, C. Scuderi, R. Dolcetti, A. Viel, D. Crivellari, E. Bidoli and M. Boiocchi, “Familial Breast Cancer: Characteristics and Outcome of BRCA 1-2 Positive and Negative Cases,” BMC Cancer, Vol. 5, 2005, p. 70.

[14]   M. O. Nicoletto, M. Donach, A. De Nicolo, G. Artioli, G. Banna and S. Monfardini, “BRCA-1 and BRCA-2 Mutations as Prognostic Factors in Clinical Practice and Genetic Counselling,” Cancer Treatment Reviews, Vol. 27, No. 5, 2001, pp. 295-304. doi:10.1053/ctrv.2001.0233